A detailed history of Vanguard Group Inc transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,256,705 shares of RLMD stock, worth $477,547. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,256,705
Previous 1,256,705 -0.0%
Holding current value
$477,547
Previous $3.77 Million 7.98%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$3.1 - $6.8 $167,710 - $367,880
-54,100 Reduced 4.13%
1,256,705 $5.84 Million
Q4 2023

Feb 14, 2024

BUY
$2.45 - $4.22 $1,886 - $3,249
770 Added 0.06%
1,310,805 $5.43 Million
Q2 2023

Aug 14, 2023

SELL
$2.22 - $3.54 $432,775 - $690,101
-194,944 Reduced 12.95%
1,310,035 $3.22 Million
Q1 2023

May 15, 2023

SELL
$2.24 - $4.76 $26,882 - $57,124
-12,001 Reduced 0.79%
1,504,979 $3.4 Million
Q4 2022

Feb 10, 2023

BUY
$2.17 - $35.84 $158,453 - $2.62 Million
73,020 Added 5.06%
1,516,980 $5.29 Million
Q3 2022

Nov 14, 2022

BUY
$18.3 - $37.02 $382,982 - $774,754
20,928 Added 1.47%
1,443,960 $53.5 Million
Q2 2022

Aug 12, 2022

BUY
$16.5 - $30.34 $1.63 Million - $3 Million
99,018 Added 7.48%
1,423,032 $27 Million
Q1 2022

May 13, 2022

BUY
$16.72 - $26.99 $1.66 Million - $2.68 Million
99,113 Added 8.09%
1,324,014 $35.7 Million
Q4 2021

Feb 14, 2022

BUY
$16.93 - $26.82 $5.25 Million - $8.32 Million
310,178 Added 33.91%
1,224,901 $27.6 Million
Q3 2021

Nov 12, 2021

BUY
$21.86 - $34.77 $3.12 Million - $4.97 Million
142,947 Added 18.52%
914,723 $24 Million
Q2 2021

Aug 13, 2021

BUY
$29.55 - $39.15 $22.8 Million - $30.2 Million
771,776 New
771,776 $24.7 Million

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.9M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.